Baird Maintains Neutral on Elevance Health, Raises Price Target to $331

Benzinga Newsdesk www.benzinga.com Positive 61.8%

Neg 0% Neu 0% Pos 61.8%

Baird analyst Michael Ha maintains Elevance Health (NYSE:ELV) with a Neutral and raises the price target from $317 to $331.